Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Accured Expenses (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Change in Accured Expenses for 5 consecutive years, with -$942000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 67.49% to -$942000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.1 million, a 37.33% increase, with the full-year FY2024 number at -$6.0 million, down 500.74% from a year prior.
  • Change in Accured Expenses was -$942000.0 for Q3 2025 at Lyra Therapeutics, down from -$202000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q3 2023 to a low of -$3.3 million in Q2 2024.
  • A 5-year average of $2578.9 and a median of -$87000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 604.32% in 2022, then plummeted 2564.37% in 2023.
  • Lyra Therapeutics' Change in Accured Expenses stood at $278000.0 in 2021, then skyrocketed by 604.32% to $2.0 million in 2022, then rose by 8.07% to $2.1 million in 2023, then plummeted by 127.17% to -$575000.0 in 2024, then crashed by 63.83% to -$942000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Change in Accured Expenses are -$942000.0 (Q3 2025), -$202000.0 (Q2 2025), and -$339000.0 (Q1 2025).